Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
Strongest Prostate Cancer Predictor Revealed
Strongest Prostate Cancer Predictor Revealed 4

Prostate cancer is a big problem worldwide, hitting 1 in 8 men at some point. Studies show it’s key to know how it will act to treat it well. It’s a complex disease, and knowing what makes it tick is essential for catching it early.strongest prostate cancer predictorNatural prostate cancer avoidance strategies

The top predictor is a mix of things like elevated PSA levels, family history, and genetic changes. We’ll dive into why these matter and how they help us fight prostate cancer. This will give us a better way to predict and handle the disease.

Key Takeaways

  • Prostate cancer is a complex disease needing a full approach to predict and treat.
  • High PSA levels are a big sign of prostate cancer.
  • Family history is key in figuring out your risk of getting prostate cancer.
  • Genetic changes can up your risk of prostate cancer.
  • Spotting and treating it early is vital for managing the disease well.

Understanding Prostate Cancer

Strongest Prostate Cancer Predictor Revealed
Strongest Prostate Cancer Predictor Revealed 5


It’s important to know about prostate cancer to catch it early and treat it well. We’ll look into what prostate cancer is, its facts, and how common it is in the U.S. This will give you a full picture of this serious disease.

Definitions and Key Facts

Prostate cancer is a tumor in the prostate gland, which is part of the male reproductive system. It happens when abnormal cells grow out of control in the prostate. Early detection is key to better treatment results. Experts say,

‘Prostate cancer is a complex disease with varying incidence rates across different populations.’

We’ll cover the main facts and definitions you need to understand prostate cancer.

Incidence Rates in the United States

In 2017, about 161,360 new cases of prostate cancer were expected in the U.S. This shows how common it is. The risk of getting prostate cancer changes with age and other factors. We’ll look at the trends and numbers of prostate cancer in the U.S. to understand it better.

Risk Factors for Prostate Cancer

Strongest Prostate Cancer Predictor Revealed
Strongest Prostate Cancer Predictor Revealed 6


Knowing the risk factors for prostate cancer is key to catching it early. Several things can increase a person’s chance of getting prostate cancer. Being aware of these can help in making smart choices about screening and prevention.

Age and Ethnicity

Age is a big risk factor for prostate cancer, with The majority of prostate cancer cases are found in men aged 65 and older. As men get older, their risk of getting prostate cancer goes up. This makes age a big deal for screening. Also, some ethnic groups have a higher risk of prostate cancer.

Key Age-Related Risk Factors:

  • Men over 65 are at a higher risk.
  • The risk increases with age.
  • Screening is recommended for older men.

Family History and Genetics

A family history of prostate cancer is another big risk factor. Men with a first-degree relative (father or brother) who had prostate cancer are at higher risk. Certain genetic mutations, like BRCA2, also raise the risk a lot.

Genetic and Familial Risk Factors:

  1. Family history of prostate cancer.
  2. Genetic mutations like BRCA2.
  3. Hereditary cancer syndromes.

Understanding these risk factors helps us find who might need earlier or more frequent screening. By knowing about age, ethnicity, family history, and genetics, we can tailor our approach to prostate cancer prevention and detection better.

The Role of PSA Testing

PSA testing is key for men to understand their prostate health. It’s a common way to screen for prostate cancer. But, knowing its limits is important for its best use.

What is PSA Testing?

PSA testing checks for a protein in the blood from the prostate gland. High levels might mean cancer, but can also show other issues. It’s not a test to say you have cancer, but to see if you need more checks.

PSA Levels and Their Interpretation

PSA levels tell us about prostate cancer risk. A level over 4 ng/mL means more tests are needed. But, even lower levels can be risky. PSA density and PSA velocity give more clues about cancer risk.

  • PSA Density: A higher ratio might mean a higher cancer risk.
  • PSA Velocity: Fast PSA increases are a warning sign for cancer.

Limitations of PSA Testing

PSA testing is useful but has limits. It can give false positives, causing worry and more tests. It also might miss slow-growing cancers, leading to overdiagnosis and treatment of small cancers.

Talking to a doctor about PSA results is vital. They can explain what the numbers mean and what to do next, based on your health and family history.

Genetic Markers and Prostate Cancer

Understanding genetic markers is key in fighting prostate cancer. They help spot people at higher risk. These markers are specific genes or mutations that show a disease risk, like prostate cancer.

Genetic factors are big in prostate cancer. Some genetic mutations raise the risk a lot.

Common Genetic Mutations

For example, the BRCA2 gene mutation is linked to higher prostate cancer risk. Men with a family history of certain cancers might want to test for these mutations.

Having mutations in BRCA1 and BRCA2 genes raises the risk, more so with a family cancer history. Knowing these risks helps in making screening plans just for you.

Emerging Research in Genetic Testing

New research aims to find more genetic markers and better testing methods. Genetic testing is getting better at finding prostate cancer-linked mutations.

Personalized medicine is becoming more common. It uses genetic info to make screening and treatment plans fit your risk. This could lead to better results by focusing on those at highest risk.

As we learn more about genetics and prostate cancer, we’ll see better genetic testing and risk checks.

The Importance of Family History

Family history is key when it comes to prostate cancer. Knowing your family’s health history helps figure out your risk. Some family patterns can make you more likely to get prostate cancer.

Why Family History Matters

Family history is important because it shows if you might be at risk for prostate cancer. Men with a family history of prostate cancer face a higher risk. This is true, even more so if their relatives got it young.

We see family history as important for a few reasons:

  • It helps find people who should get checked early.
  • It helps us understand the genetic factors.
  • It guides decisions on prevention and watching for signs.

Examples of High-Risk Patterns

Some family history patterns raise the risk of prostate cancer. For example:

Family History Pattern

Risk Level

Having a father or brother diagnosed with prostate cancer

Increased risk

Having multiple first-degree relatives (father, brothers) diagnosed

Higher risk

Having relatives diagnosed at a younger age (less than 65 years)

Significantly higher risk

Knowing these patterns helps us spot people at higher risk. This lets us focus on early screening and treatment.

Lifestyle Factors Influencing Prostate Cancer

Lifestyle choices are key in determining prostate cancer risk. We see how certain habits can greatly affect this risk.

Diet and Nutrition

Diet and nutrition are vital for a healthy life. They have a big impact on prostate cancer risk. Eating lots of fruits, vegetables, and whole grains is good for health.

Nutrients and Foods: Some foods and nutrients may help lower prostate cancer risk. For example, tomatoes and fish are good choices.

  • Lycopene-rich foods (e.g., tomatoes, tomato products)
  • Omega-3 fatty acids (e.g., fatty fish like salmon)
  • Green tea
  • Cruciferous vegetables (e.g., broccoli, cauliflower)

Physical Activity

Physical activity is linked to prostate cancer risk. Exercise is good for health and may protect against prostate cancer.

Types of Physical Activity: Walking, cycling, and strength training are all good. The goal is to do moderate exercise regularly.

“Regular physical activity is associated with a reduced risk of prostate cancer, highlighting the importance of incorporating exercise into daily routines.”

— American Cancer Society

Smoking and Alcohol Use

Smoking and drinking alcohol are lifestyle choices that affect prostate cancer risk. While the evidence is not as strong as for other cancers, smoking might raise the risk of aggressive prostate cancer.

Lifestyle Factor

Potential Impact on Prostate Cancer Risk

Smoking

May increase the risk of aggressive prostate cancer

Alcohol Use

Mixed evidence; excessive consumption may have negative effects

In conclusion, lifestyle factors like diet, exercise, smoking, and alcohol use are important for prostate cancer risk. Making smart choices can help lower this risk.

Advanced Diagnostic Techniques

We use advanced methods to better diagnose and stage prostate cancer. These methods help us understand how far the cancer has spread. This information is key to choosing the right treatment.

MRI and Imaging Methods

Magnetic Resonance Imaging (MRI) has changed how we find prostate cancer. An abnormal prostate MRI shows cancer cells might be present. This helps doctors spot patients at high risk.

MRI gives clear pictures of the prostate gland. It helps find tumors and where they are. Other methods like ultrasound and CT scans also help, but MRI is best for detailed images.

Biopsy Procedures

A biopsy is the main way to confirm prostate cancer. Prostate biopsy indicators include high PSA levels and abnormal digital rectal exams. Suspicious images also point to a biopsy.

During a biopsy, tissue samples are taken from the prostate. These are checked for cancer cells. The method used and the doctor’s skill affect how accurate the results are.

Advanced biopsy techniques, like MRI-guided biopsy, improve finding significant cancer. This lowers the chance of missing cancer or treating it too much.

Prioritizing Risk Assessment Tools

Prostate cancer risk assessment has evolved with new risk calculators. These tools help spot high-risk individuals early. This can lead to better treatment results. We’ll look at how risk calculators work and some examples used in clinics.

Role of Risk Calculators

Risk calculators predict prostate cancer risk based on age, family history, and genetics. They help doctors find patients who need closer screening. Using these calculators makes prostate cancer screening more targeted.

Examples of Assessment Tools Used

Many risk assessment tools exist, each with its own strengths. Some key ones are:

  • The Prostate Cancer Prevention Trial (PCPT) Risk Calculator
  • The European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator
  • The Prostate Biopsy Collaborative Group (PBCG) Risk Calculator

These tools differ in what they consider and what they show. But they all aim to give a clearer picture of prostate cancer risk.

Risk Calculator

Key Factors Considered

Primary Use

PCPT Risk Calculator

Age, PSA level, family history, ethnicity

General risk assessment

ERSPC Risk Calculator

PSA level, digital rectal examination findings

Screening decisions

PBCG Risk Calculator

PSA level, age, biopsy history

Biopsy decision-making

Healthcare providers use these tools to make smarter choices about prostate cancer screening. It’s vital to keep these tools updated with new research and findings.

Treatment Outcomes Based on Predictors

The strongest predictors of prostate cancer greatly affect treatment outcomes and patient prognosis. It’s key to understand these predictors for effective treatment plans.

How Predictors Affect Treatment Choices

PSA levels, Gleason score, and family history are key in choosing treatments. For example, a high Gleason score means the cancer might be aggressive. This could lead to more intense treatments.

We use these predictors to make sure patients get the right care for their condition.

Prognosis with Different Risk Levels

Prostate cancer prognosis changes a lot based on risk level. Patients with low-risk cancer usually have a better outlook than those with high-risk cancer.

We look at PSA levels, Gleason score, and clinical stage to give a precise prognosis.

Predictor

Low Risk

High Risk

PSA Level

< 10 ng/mL

> 20 ng/mL

Gleason Score

6 or less

8 or higher

Clinical Stage

T1-T2a

T3-T4

Prognosis

Favorable

Poor

Knowing how predictors impact treatment and prognosis helps us tailor plans. This improves patient outcomes.

Community and Support Resources

Going through prostate cancer is easier with the right support. Having access to support groups and educational resources is key. A supportive community helps patients face the challenges of prostate cancer.

Support Groups and Networks

Support groups offer a place for patients and families to share and get support. They can meet in person or online, fitting different needs.

The benefits of support groups include:

  • Emotional support from those who know the challenges of prostate cancer
  • Advice on managing treatment side effects from others who have been there
  • Access to resources and information from healthcare experts and peers

Notable support networks include the Us TOO Prostate Cancer Support and the Prostate Cancer Foundation. They offer a variety of services and support.

Educational Resources

Educational resources give patients the knowledge they need. They learn about prostate cancer, treatment options, and managing side effects. These include online portals, literature, and workshops.

Examples of educational resources include:

  1. The American Cancer Society website, which has detailed information on prostate cancer
  2. Patient education literature on diagnosis, treatment, and survivorship
  3. Workshops and seminars by healthcare institutions and cancer support groups

Using these resources, patients can make better decisions about their care. This improves their quality of life.

Conclusion: Advocating for Awareness and Screening

Early detection is key to better outcomes in prostate cancer. Knowing the strongest signs of this disease helps spread awareness. It also encourages men to get screened.

Using early signs like prostate-specific antigen trends makes screenings more effective. This way, doctors can help those at higher risk. It leads to better treatment results.

Promoting Prostate Health

We need to keep pushing for better prostate health. This means teaching men about the importance of catching cancer early. We should also help them talk to their doctors about their risks.

Advancing Screening and Detection

Improving our knowledge of prostate cancer and screening methods is vital. This effort can lessen the disease’s impact. Raising awareness is essential for this goal. We must support efforts in education, research, and early detection.

FAQ

What are the strongest predictors of prostate cancer?

The main factors include high PSA levels, family history, and genetic mutations like BRCA2. Knowing these helps find cancer early and treat it better.

How does age influence the risk of prostate cancer?

Age is a big risk factor. Most cases are found in men over 65. As men get older, their risk goes up.

What is the role of PSA testing in prostate cancer detection?

PSA testing is key for finding prostate cancer early. It checks the blood for prostate-specific antigen, which can be high in cancer cases.

How do genetic mutations affect the risk of prostate cancer?

Mutations, like BRCA2, raise the risk a lot. Knowing about these can help tailor screening and prevention plans.

Why is family history important in assessing prostate cancer risk?

Family history is very important. Men with a family history of prostate cancer are at higher risk.

How do lifestyle factors influence prostate cancer risk?

Lifestyle choices like diet, exercise, smoking, and alcohol use affect risk. A healthy lifestyle can lower the risk.

What is the significance of PSA density and velocity in prostate cancer detection?

PSA density and velocity are key signs of risk. High density and fast velocity mean higher risk.

How do advanced diagnostic techniques aid in prostate cancer diagnosis?

Techniques like MRI and biopsy are vital for accurate diagnosis and staging of prostate cancer.

What is the role of risk assessment tools in prostate cancer screening?

Tools like risk calculators help find those at high risk. This leads to personalized screening and prevention plans.

How do predictors affect treatment choices and prognosis in prostate cancer?

Knowing how predictors affect treatment and prognosis is key. Different factors influence treatment decisions and outcomes.

What resources are available for patients living with prostate cancer?

Support groups, networks, and educational resources are essential. They offer guidance and support to patients and their families.

Why is early detection and screening important for prostate cancer?

Early detection and screening are critical for better outcomes. Finding cancer early improves treatment options and survival rates.


References

National Center for Biotechnology Information. Evidence-Based Medical Insight. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC1476014/

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Get a Free Quote

Response within 2 hours during business hours

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
Trusted Worldwide
30
Years of
Experience
30 Years Badge
Health Türkiye Accreditation

Trusted Worldwide

30 Years of Experience

Patient Reviews
Reviews from 9,651
4,9
Was this content helpful?
Your feedback helps us improve.
What did you like?
Share more details about your experience.
You must give consent to continue.

Thank you!

Your feedback has been submitted successfully. Your input is valuable in helping us improve.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 510 67 91